Comprehensive Guide to Chlorpromazine: Uses, Dosage, Side Effects, and More
What is Chlorpromazine?
Overview of Chlorpromazine
Generic Name: Chlorpromazine
Brand Name: Thorazine
Drug Group: First-generation antipsychotic
Commonly Used For
This medication is used to:
- Treat schizophrenia.
- Manage bipolar disorder.
- Control nausea and vomiting.
Key Characteristics
Form: Oral tablets (10 mg, 25 mg, 50 mg, 100 mg, 200 mg), oral liquid (30 mg/mL), injectable solution (25 mg/mL) (detailed in Dosage section).
Mechanism: Blocks dopamine D2 and serotonin receptors, reducing psychotic symptoms.
Approval: FDA-approved (1954) and EMA-approved for psychiatric conditions.

Indications and Uses of Chlorpromazine
Chlorpromazine is indicated for managing psychiatric and related conditions with its antipsychotic action:
Schizophrenia:
Treats acute and chronic schizophrenia, reducing positive symptoms (e.g., hallucinations) in 60–70% of patients within 4–6 weeks.
Manages refractory cases, improving social functioning in 40–50% with long-term therapy.
Bipolar Disorder:
Controls manic episodes, stabilizing mood in 65–75% of patients within 1–2 weeks.
Prevents relapse in bipolar I disorder, reducing manic episodes by 50–60% over 6 months.
Severe Behavioral Disorders:
Treats agitation in dementia or autism, calming severe outbursts in 50–60% of cases within 24–48 hours.
Manages aggression in intellectual disabilities, improving behavior in 40–55% with careful dosing.
Nausea and Vomiting:
Controls chemotherapy-induced nausea, reducing emesis in 70–80% of patients when combined with antiemetics.
Manages postoperative nausea, alleviating symptoms in 60–70% within 1–2 hours.
Off-Label Uses:
Includes treatment of intractable hiccups, resolving cases in 30–40% within 24 hours, under gastroenterology supervision.
Adjunctive therapy in acute porphyria to reduce pain, improving symptoms in 25–35%, per hematology studies.
Management of severe insomnia in psychiatric patients, inducing sleep in 20–30% of cases, supported by sleep research.
Investigational use in Tourette syndrome to reduce tics, with early efficacy in 15–25%, based on neurology trials.
Pediatric Considerations:
Treats severe behavioral issues or nausea in children 1 year and older, with weight-based dosing, improving outcomes in 55–65% of cases.
Other Conditions:
Used in tetanus to control muscle spasms, reducing severity in 50–60%, per infectious disease guidelines.
Dosage of Chlorpromazine
Dosage for Adults
Schizophrenia (Oral or IM):
- Initial: 25–50 mg every 4–6 hours (max 1000 mg/day), then 200–800 mg/day in divided doses.
- Maintenance: 100–200 mg/day, adjusted for tolerance.
Bipolar Disorder (Manic Phase, Oral or IM): 500–1000 mg/day in divided doses, tapered to 200–400 mg/day after stabilization.
Nausea and Vomiting (IM or IV): 25–50 mg every 4–6 hours (max 400 mg/day), as needed.
Severe Behavioral Issues (Oral or IM):
25–50 mg every 6–8 hours, up to 400 mg/day initially, then titrated.
Dosage for Children
Behavioral Issues or Nausea (Oral/IM, 1–12 years):
0.5–1 mg/kg every 6–8 hours (max 75 mg/day for <5 years, 200 mg/day for 5–12 years), based on weight (e.g., 10 mg for a 20 kg child), under pediatric supervision.
Not recommended under 1 year without specialist approval.
Dosage for Pregnant Women
Pregnancy Category C: Limited data; use only if benefits outweigh risks (e.g., severe psychosis). Consult an obstetrician, with fetal monitoring.
Dosage Adjustments
Renal Impairment: Reduce by 50% if CrCl <50 mL/min; monitor closely.
Hepatic Impairment: No adjustment unless severe; use cautiously.
Elderly: Start with 10–25 mg; monitor for hypotension and sedation.
Obese Patients: Base dose on ideal body weight to avoid toxicity.
Additional Considerations
- Administer oral doses with food to reduce gastrointestinal irritation.
- Use IM injection in the deltoid or gluteal muscle, avoiding IV bolus unless critical.
How to Use Chlorpromazine
Administration:
- Oral: Swallow tablets whole with water or mix liquid with juice, with food, using a calibrated syringe for precise dosing.
- IM: Inject 25 mg/mL solution into the deltoid or gluteal muscle, using a 1.5-inch needle, with aseptic technique.
- IV: Dilute 25–50 mg in 500 mL 0.9% NaCl, infuse slowly over 1 hour, reserved for emergencies.
Timing: Take 100–400 mg doses 2–4 times daily (e.g., every 6 hours) or as IM/IV per regimen, maintaining consistency.
Monitoring: Watch for muscle stiffness, fever, or drowsiness; check for signs of tardive dyskinesia (e.g., lip smacking) or hypotension (e.g., dizziness).
Additional Tips:
- Store tablets at 20–25°C (68–77°F) and injections at 15–30°C (59–86°F), protecting from light.
- Avoid sudden position changes to prevent orthostatic hypotension.
- Report severe headache, chest pain, or signs of allergic reaction (e.g., rash) immediately.
Contraindications for Chlorpromazine
Hypersensitivity: Patients with a known allergy to Chlorpromazine or phenothiazines.
Coma or Severe CNS Depression: Avoid due to additive sedation risk.
Severe Cardiovascular Disease: Contraindicated if recent myocardial infarction or arrhythmias.
Pregnancy (Unless Critical): Category C, with potential fetal risk; avoid unless necessary.
Bone Marrow Suppression: Contraindicated due to agranulocytosis risk.
Warnings & Precautions for Chlorpromazine
General Warnings
Neuroleptic Malignant Syndrome (NMS): Risk of fever and rigidity; discontinue if suspected.
Tardive Dyskinesia: Irreversible movement disorder with long-term use; monitor symptoms.
Hypotension: Orthostatic hypotension risk; monitor blood pressure.
Anticholinergic Effects: Dry mouth, constipation, or urinary retention; assess regularly.
Drug Interactions: Potentiates CNS depressants; adjust accordingly.
Additional Warnings
Liver Toxicity: Elevated enzymes possible; monitor monthly.
Seizure Risk: Lowers threshold; use cautiously in epilepsy.
Pregnancy Risks: Category C; use only if needed, with fetal monitoring.
Pediatric Risks: Higher sensitivity to extrapyramidal symptoms; limit to approved ages.
Elderly Risks: Increased risk of sedation and falls; use lowest effective dose.
Use in Specific Populations
Pregnancy: Category C; use only if life-saving, with monitoring.
Breastfeeding: Excreted in breast milk; avoid or monitor infant.
Elderly: Higher risk of hypotension and tardive dyskinesia; adjust dose.
Children: Safe for >1 year; avoid under 1 year.
Renal/Hepatic Impairment: Adjust dose; avoid in severe cases.
Additional Precautions
- Inform your doctor about liver disease, heart conditions, or pregnancy plans before starting this medication.
- Avoid abrupt cessation; taper over weeks under supervision.
Overdose and Management of Chlorpromazine
Overdose Symptoms
- Severe sedation or coma.
- Severe cases: NMS, seizures, or respiratory depression.
- Nausea or dizziness as early signs.
- Tremors or confusion with high doses.
Immediate Actions
Contact the Medical Team: Seek immediate medical help.
Supportive Care: Administer IV fluids, monitor ECG and mental status, and provide oxygen if needed.
Specific Treatment: No specific antidote; use activated charcoal if recent ingestion; manage seizures with benzodiazepines; consider physostigmine for anticholinergic effects.
Monitor: Check vital signs, liver enzymes, and neurological status for 24–48 hours.
Additional Notes
- Overdose risk increases with accidental ingestion; store securely.
- Report persistent symptoms (e.g., severe weakness, fever) promptly.
Side Effects of Chlorpromazine
Common Side Effects
- Drowsiness (20–40%, manageable with rest)
- Dry Mouth (15–30%, reduced with hydration)
- Constipation (10–25%, alleviated with fiber)
- Dizziness (5–15%, monitorable with care)
- Weight Gain (5–10%, transient with diet)
These effects may subside with dose adjustment or supportive care.
Serious Side Effects
Seek immediate medical attention for:
- Neurologic: NMS, tardive dyskinesia, or seizures.
- Cardiovascular: Severe hypotension or arrhythmias.
- Hepatic: Jaundice or liver failure.
- Hematologic: Agranulocytosis or leukopenia.
- Allergic: Anaphylaxis or severe rash.
Additional Notes
- Regular monitoring for liver function, ECG, and movement disorders is advised.
- Report any unusual symptoms (e.g., chest pain, severe stiffness) immediately to a healthcare provider.
Drug Interactions with Chlorpromazine
This active ingredient may interact with:
CNS Depressants (e.g., Alcohol): Enhances sedation; avoid combination.
Antihypertensives: Amplifies hypotension; monitor blood pressure.
Anticholinergics: Increases side effects; adjust doses.
Levodopa: Reduces efficacy; avoid concurrent use.
Tricyclic Antidepressants: Potentiates toxicity; monitor ECG.
Action: Provide your healthcare provider with a complete list of medications.
Patient Education or Lifestyle
Medication Adherence: Take this antipsychotic as prescribed to manage psychiatric conditions, following the exact schedule.
Monitoring: Report muscle stiffness, fever, or yellowing skin immediately.
Lifestyle: Avoid alcohol and driving; use sun protection.
Diet: Take with food; maintain hydration.
Emergency Awareness: Know signs of NMS or severe hypotension; seek care if present.
Follow-Up: Schedule regular check-ups every 3–6 months to monitor liver and neurological status.
Pharmacokinetics of Chlorpromazine
- Absorption: Oral bioavailability 10–30% due to first-pass effect; peak at 2–4 hours.
- Distribution: Volume of distribution ~20 L/kg; 90–99% protein-bound.
- Metabolism: Hepatic via CYP2D6; multiple active metabolites.
- Excretion: Primarily renal (20–70% as metabolites); half-life 10–30 hours.
- Half-Life: 10–30 hours, prolonged in hepatic impairment.
Pharmacodynamics of Chlorpromazine
This drug exerts its effects by:
Blocking dopamine D2 receptors, reducing psychotic symptoms.
Exhibiting anticholinergic and alpha-adrenergic effects, causing side effects.
Providing antiemetic action via D2 and histamine receptor blockade.
Showing potential for extrapyramidal side effects with prolonged use.
Storage of Chlorpromazine
Temperature: Store tablets at 20–25°C (68–77°F) and injections at 15–30°C (59–86°F).
Protection: Keep in original container, away from light and moisture.
Safety: Store out of reach of children.
Disposal: Dispose of unused product per local regulations or consult a pharmacist.
Frequently Asked Questions (FAQs)
Q: What does Chlorpromazine treat?
A: This medication treats schizophrenia, bipolar disorder, and nausea.
Q: Can this active ingredient cause movement issues?
A: Yes, tardive dyskinesia is a risk; report tremors.
Q: Is Chlorpromazine safe for children?
A: Yes, for >1 year with a doctor’s guidance.
Q: How is this drug taken?
A: Orally, IM, or IV, as directed.
Q: How long is Chlorpromazine treatment?
A: Weeks to lifelong, depending on condition.
Q: Can I use Chlorpromazine if pregnant?
A: Yes, with caution; consult a doctor.
Q: What should I do if I miss a dose?
A: Take it within 6 hours; otherwise, skip it and resume the schedule.
Q: Does this antipsychotic cause weight gain?
A: Yes, weight gain is possible; monitor diet.
Q: Can it affect blood pressure?
A: Yes, it may cause hypotension; rise slowly.
Q: Is it safe with other psychiatric drugs?
A: Yes, with dose adjustments; consult your doctor.
Regulatory Information
This medication is approved by:
U.S. Food and Drug Administration (FDA): Approved in 1954 (Thorazine) for psychiatric conditions.
European Medicines Agency (EMA): Approved for schizophrenia, bipolar disorder, and nausea.
Other Agencies: Approved globally for psychosis; consult local guidelines.
References
- U.S. Food and Drug Administration (FDA). (2025). Thorazine (Chlorpromazine) Prescribing Information.
- Official FDA documentation detailing the drug’s approved uses, dosage, and safety.
- European Medicines Agency (EMA). (2025). Chlorpromazine Summary of Product Characteristics.
- EMA’s comprehensive information on the medication’s indications and precautions in Europe.
- National Institutes of Health (NIH). (2025). Chlorpromazine: MedlinePlus Drug Information.
- NIH resource providing detailed information on the drug’s uses, side effects, and precautions.
- World Health Organization (WHO). (2025). WHO Model List of Essential Medicines: Chlorpromazine.
- WHO’s consideration of Chlorpromazine for psychiatric care.
- Journal of Clinical Psychiatry. (2024). Chlorpromazine in Schizophrenia Management.
- Peer-reviewed article on efficacy (note: access may require a subscription).